Functional study on Boswellia phytosome as complementary intervention in asthmatic patients

Area of Science:

• Respiratory Medicine
• Pharmacology
• Integrative Medicine

Background:

• Standard asthma management involves inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs).
• Patients often seek complementary or alternative therapies due to limitations in current treatments.
• Investigating adjuncts to standard ICS + LABA therapy is crucial for improving asthma control.

Purpose of the Study:

• To evaluate the efficacy of Casperome® as an add-on therapy for persistent asthma.
• To determine if Casperome® can reduce the reliance on standard ICS + LABA inhaler treatments.
• To assess the safety and tolerability of Casperome® in asthma patients.

Main Methods:

• A multicenter study randomized 32 asthma patients already on ICS + LABAs.
• Participants received either 500 mg/day of Casperome® or no additional treatment for 4 weeks.
• Daily inhalations and adverse events were meticulously recorded.

Main Results:

• Patients taking Casperome® showed a significant decrease in the number of daily inhalations required.
• The addition of Casperome® to ICS + LABA therapy was well-tolerated.
• Only mild to moderate adverse events were reported during the study period.

Conclusions:

• Casperome® 500 mg/day demonstrates a beneficial effect in managing persistent asthma.
• This supplement can help reduce the need for rescue inhaler use in asthma patients.
• Casperome® represents a potentially valuable complementary therapy for asthma management.